# TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients

> **NCT04066543** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DEVICE:** TACE
- **DRUG:** Anlotinib Hydrochloride

## Key facts

- **NCT ID:** NCT04066543
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-30
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-10-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04066543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04066543, "TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04066543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*